U.K. Supreme Court deals Pfizer setback in Lyrica case

A U.K. Supreme Court decision will likely make it more difficult for branded drugmakers to protect the exclusivity of their products within related indications with its Wednesday decision that invalidated second medical use patent claims for Lyrica pregabalin from Pfizer Inc. (NYSE:PFE) on the grounds of insufficiency.

The ruling reiterates that "plausibility is a requirement

Read the full 545 word article

User Sign In